tiprankstipranks
Trending News
More News >
23Andme Holding Co (ME)
NASDAQ:ME
US Market
Advertisement

23andMe Holding (ME) Price & Analysis

Compare
1,321 Followers

ME Stock Chart & Stats


Financials

Ownership Overview

47.58%12.85%5.18%30.04%
47.58% Insiders
5.18% Other Institutional Investors
30.04% Public Companies and
Individual Investors

ME FAQ

What was 23Andme Holding Co’s price range in the past 12 months?
23Andme Holding Co lowest stock price was $0.48 and its highest was $12.76 in the past 12 months.
    What is 23Andme Holding Co’s market cap?
    23Andme Holding Co’s market cap is $16.27M.
      When is 23Andme Holding Co’s upcoming earnings report date?
      23Andme Holding Co’s upcoming earnings report date is May 22, 2025 which is 62 days ago.
        How were 23Andme Holding Co’s earnings last quarter?
        Currently, no data Available
        Is 23Andme Holding Co overvalued?
        According to Wall Street analysts 23Andme Holding Co’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does 23Andme Holding Co pay dividends?
          23Andme Holding Co does not currently pay dividends.
          What is 23Andme Holding Co’s EPS estimate?
          23Andme Holding Co’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does 23Andme Holding Co have?
          23Andme Holding Co has 19,721,802 shares outstanding.
            What happened to 23Andme Holding Co’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of 23Andme Holding Co?
            Currently, no hedge funds are holding shares in ME

            Company Description

            23Andme Holding Co

            23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
            Similar Stocks
            Company
            Price & Change
            Follow
            Illumina
            Myriad Genetics
            Qiagen
            Guardant Health
            Twist Bioscience
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis